BC Innovations | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BC Extra | Oct 1, 2019
Company News

ElevateBio launches HighPassBio with TCR immunotherapy focus

Less than five months after its launch, ElevateBio has announced a second portfolio company: HighPassBio, which is developing T cell immunotherapies based on research from the Fred Hutchinson Cancer Research Center. HighPassBio’s lead candidate is...
BC Innovations | Aug 15, 2019
Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

Adaptive’s float to more than $5 billion after its June IPO is largely based on its ambition to compete with the likes of Grail and Guardant in early diagnosis of cancer and other diseases by...
BC Week In Review | Sep 21, 2018
Clinical News

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with alpha fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) in a...
BC Week In Review | Jul 27, 2018
Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on July 23. Sangamo expects to be the first company to...
BC Extra | Jul 23, 2018
Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on Monday. Sangamo expects to be the first company to bring...
BC Innovations | Apr 12, 2018
Translation in Brief

Shape recognition

A Cardiff University team has engineered a D-peptide that mimicked the T cell agonist activity of an influenza peptide and protected mice from infection by the virus. The findings suggest oral vaccines based on synthetic...
BC Innovations | Apr 3, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Mouse studies suggest a vaccine based on an M1-mimicking synthetic peptide could help treat influenza. Screening of a combinatorial library of D-peptides against CD8 + T cell clones specific for the immunodominant...
BC Innovations | Mar 19, 2018
Translation in Brief

Crafting CAR Tregs

TxCell S.A. (Euronext:TXCL) thinks it has cracked the code on building CAR Tregs without running into the manufacturing challenges that can compromise the cells’ immunosuppressive function. The company presented data on their manufacturing process at...
BioCentury | Dec 16, 2017
Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
Items per page:
1 - 10 of 49